Compare Align Technology, Inc. (ALGN) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Enveric Biosciences Inc — how do they compare? Align Technology, Inc. trades at $172.72 (market cap $12.51B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Align Technology, Inc. is far larger — about 2017.7× Enveric Biosciences Inc's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | ENVB | |
|---|---|---|
Market Cap | $12.51B | $6.20M |
Sector | Health | Health |
52-Week High | $197.51 | $17.40 |
52-Week Low | $124.88 | $1.27 |
Enterprise Value | $11.52B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.66, up 2.71% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $2.64 surpassing the $2.62 estimate. Revenue reached a record $1.06 billion in Q2 2026, driven by clear aligner growth. Recent board changes and strategic initiatives aim to enhance long-term value.
The outlook is positive, supported by robust fundamentals and institutional interest, but risks include competitive pressures and scanner segment weakness. Valuation multiples remain below historical peaks, offering potential upside if growth accelerates. Investor sentiment is cautiously optimistic amid ongoing operational reviews.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
